Plasma oxytocin levels in response to glucagon in patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls

What Was Tested

Researchers studied Oxytocin and Glucagon in this randomized controlled trial publication.

However, the implication of the MDMA provocation test in clinical practice might be challenging.

The researchers therefore hypothesized that this provocation test might also stimulate OT.

The primary objective was to determine whether glucagon stimulates OT and whether OT levels differ between patients with AVP deficiency and healthy participants.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

This is a predefined secondary analysis of a prospective double-blind, randomised, placebo-controlled cross-over trial involving ten patients with AVP deficiency and ten sex- and body-mass index-matched healthy participants at the University Hospital Basel, Switzerland.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Oxytocin and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Oxytocin.

Some participants received a placebo instead of Oxytocin, giving a reference point.

In the crossover set-up each of the participants took both Oxytocin and the comparison in turn, acting as their own control.

Plasma OT levels were measured at baseline, 60, 120 and 180 min after injection.

The primary outcome (maximum change in OT within 180 min) was compared between groups and conditions using a linear mixed effects model.

What Was Measured

The subject headings attached to it are Glucagon, Oxytocin, Arginine Vasopressin and Diabetes Insipidus, Neurogenic.

Author keywords: Glucagon test, Hypopituitarism, Pituitary and Stimulation test.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Oxytocin and Glucagon.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Endocrine), a journal based in United States.

More context: the Oxytocin compound page and the Glucagon compound page, all human trials.